Stockreport

How TP-05's Phase 2 Lyme Prophylaxis Trial Progress Could Impact Tarsus Pharmaceuticals (TARS) Investors [Yahoo! Finance]

Tarsus Pharmaceuticals, Inc.  (TARS) 
PDF This program targets a large unmet need as a potential first-in-class, non-vaccine, drug-based prophylactic for Lyme disease, where no FDA-approved preventive drugs cur [Read more]